TY - JOUR
T1 - Severe thrombocytopenia caused by simvastatin in which thrombocyte recovery was initiated after severe bacterial infection
AU - Yamada, Tetsuya
AU - Shinohara, Kenji
AU - Katsuki, Kensaku
PY - 1998/9/30
Y1 - 1998/9/30
N2 - Inhibitors of 3-hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase have been used increasingly for the treatment of hypercholesteroaemia. Rare adverse effects of rhabdomyolysis, myopathy, cataracts, rashes, gastrointestinal symptoms, insomnia, hyperkalaemia and proteinuria have been reported. In addition, a few cases of thrombocytopenia have been reported in postmarketing surveys and case reports. In the case presented here, severe thrombocytopenia appeared to have been caused by simvastatin. The condition responded poorly to initial corticosteroid treatment, but thrombocyte recovery was initiated after severe bacterial infection. The initial thrombocyte recovery response may be via a cytokine with thrombopoietic activity such as interleukin (IL)-6, which has been shown to be released during the severe inflammatory process.
AB - Inhibitors of 3-hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase have been used increasingly for the treatment of hypercholesteroaemia. Rare adverse effects of rhabdomyolysis, myopathy, cataracts, rashes, gastrointestinal symptoms, insomnia, hyperkalaemia and proteinuria have been reported. In addition, a few cases of thrombocytopenia have been reported in postmarketing surveys and case reports. In the case presented here, severe thrombocytopenia appeared to have been caused by simvastatin. The condition responded poorly to initial corticosteroid treatment, but thrombocyte recovery was initiated after severe bacterial infection. The initial thrombocyte recovery response may be via a cytokine with thrombopoietic activity such as interleukin (IL)-6, which has been shown to be released during the severe inflammatory process.
UR - http://www.scopus.com/inward/record.url?scp=0031680021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031680021&partnerID=8YFLogxK
U2 - 10.2165/00044011-199816020-00011
DO - 10.2165/00044011-199816020-00011
M3 - Article
C2 - 18370536
AN - SCOPUS:0031680021
VL - 16
SP - 172
EP - 174
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
SN - 1173-2563
IS - 2
ER -